Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Nov;190(1):155-163.
doi: 10.1007/s10549-021-06365-7. Epub 2021 Aug 18.

HER2-low status and response to neoadjuvant chemotherapy in HER2 negative early breast cancer

Luciana de Moura Leite  1 , Marcelle Goldner Cesca  2 , Monique Celeste Tavares  2 , Debora Maciel Santana  2 , Erick Figueiredo Saldanha  2 , Paula Tavares Guimarães  2 , Daniella Dias Silva Sá  2 , Maria Fernanda Evangelista Simões  2 , Rafael Lima Viana  2 , Francisca Giselle Rocha  2 , Simone Klog Loose  2 , Sinara Figueiredo Silva  2 , Rafaela Pirolli  2 , Camilla Albina Zanco Fogassa  2 , Bruna Raphaeli Silva Mattos  2 , Fernando Augusto Batista Campos  2 , Solange Moraes Sanches  2 , Vladmir Cláudio Cordeiro de Lima  2 , Noam Falbel Pondé  2
Affiliations

HER2-low status and response to neoadjuvant chemotherapy in HER2 negative early breast cancer

Luciana de Moura Leite et al. Breast Cancer Res Treat. 2021 Nov.

Abstract

Purpose: Knowledge on whether low expressions of HER2 have prognostic impact in early-stage breast cancer (BC) and on its response to current chemotherapy protocols can contribute to medical practice and development of new drugs for this subset of patients, changing treatment paradigms. This study aims to evaluate the impact of HER2-low status on response to neoadjuvant chemotherapy (NACT) and survival outcomes in early-stage HER2-negative BC.

Methods: Records from all BC patients treated with NACT from January 2007 to December 2018 in a single cancer center were retrospectively reviewed. HER2-negative (immunohistochemistry [IHC] 0, + 1, or + 2 non-amplified by in situ hybridization [ISH]) patients were included. HER2-low was defined by IHC + 1 or + 2 ISH non-amplified and HER2-0 by IHC 0. The coprimary objectives were to compare pathological complete response (pCR) and relapse-free survival (RFS) between luminal/HER2-low versus luminal/HER2-0 populations and between triple negative (TNBC)/HER2-low versus TNBC/HER2-0.

Results: In total, 855 HER2-negative patients were identified. The median follow-up was 59 months. 542 patients had luminal subtype (63.4%) and 313 had TNBC (36.6%). 285 (33.3%) were HER2-low. Among luminal patients, 145 had HER2 IHC + 1 (26.8%) and 91 had IHC + 2/ISH non-amplified (16.8%). In TNBC, 36 had HER2 IHC + 1 (11.5%) and 13 had IHC + 2/ISH non-amplified (4.2%). Most patients had locally advanced tumors, regardless of subtype or HER2-low status. For luminal disease, pCR was achieved in 13% of HER2-low tumors versus 9.5% of HER2-0 (p = 0.27). Similarly, there was no difference in pCR rates among TNBC: 51% versus 47% in HER2-low versus HER2-0, respectively (p = 0.64). HER2-low was also not prognostic for RFS, with 5-year RFS rates of 72.1% versus 71.7% (p = 0.47) for luminal HER2-low/HER2-0, respectively, and 75.6% versus 70.8% (p = 0.23) for TNBC HER2-low/HER2-0.

Conclusion: Our data does not support HER2-low as a biologically distinct BC subtype, with no prognostic value on survival outcomes and no predictive effect for pCR after conventional NACT.

Keywords: Antibody–drug conjugates; HER2; HER2-low breast cancer; Trastuzumab–deruxtecan; Trastuzumab–duocarmazine.

PubMed Disclaimer

References

    1. Goutsouliak K, Veeraraghavan J, Sethunath V et al (2020) Towards personalized treatment for early stage HER2-positive breast cancer. Nat Rev Clin Oncol 17:233–250. https://doi.org/10.1038/s41571-019-0299-9 - DOI - PubMed
    1. Cesca MG, Vian L, Cristóvão-Ferreira S et al (2020) HER2-positive advanced breast cancer treatment in 2020. Cancer Treat Rev 88:102033. https://doi.org/10.1016/j.ctrv.2020.102033 - DOI - PubMed
    1. Slamon DJ, Clark GM, Wong SG et al (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. https://doi.org/10.1126/science.3798106 - DOI - PubMed
    1. Cameron D, Piccart-Gebhart MJ, Gelber RD et al (2017) 11 years’ follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. Lancet 389:1195–1205. https://doi.org/10.1016/S0140-6736(16)32616-2 - DOI - PubMed - PMC
    1. Delaloge S, Antoine A, Debled M et al (2020) 279MO Divergent evolution of overall survival across metastatic breast cancer (MBC) subtypes in the nationwide ESME real life cohort 2008–2016. Ann Oncol 31:S352–S353. https://doi.org/10.1016/j.annonc.2020.08.381 - DOI

Substances

LinkOut - more resources